Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix's Shares Jump 30 Percent in June to Lead GWDN Index

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Affymetrix climbed 30 percent in June after the firm announced early in the month that Frank Witney had rejoined the company, replacing Kevin King as president and CEO.

Affymetrix, which is currently trading at a 52-week high, led all shares in the GenomeWeb Daily News Index.

Two other firms, Exact Sciences (+15 percent) and Caliper Life Sciences (+13 percent), also rose in the double digits in an otherwise down month for many of the stocks in the Index.

Exact's stock climbed in the past two weeks. Wedbush Securities recently initiated coverage on the firm with an "Outperform" rating and a $10 price target.

Rosetta Genomics had the steepest decline among the stocks that lost ground for the month. Rosetta fell around 33 percent in June and is down 69 percent for the year.

Among the other stocks that dropped significantly during the month were Nanosphere (-29 percent), Accelr8 (-24 percent), and Vermillion (-24 percent).

Overall, the GWDN Index was down nearly 2 percent, matching the drop for both the Nasdaq and Nasdaq Biotech Index. The Dow Jones Industrial Average lost 1 percent.


The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.